Table 4.
Previous studies reporting EAD tumors treated with CA.
| Reference | No. of Patients | No. of EAD Tumors | EAD Tumor Size Before CA | No. of CA Treatments | CA as First-Line Treatment | Mean Follow-Up Time (Months) | Imaging Follow-Up | Follow-Up Scheme (Months) | Partial Treatment with CA | Complete Treatment with CA | Residual Viable EAD Tumors | Reduction in EAD Tumor Volume at Last Follow-Up | No. of Recurrence/Disease Progression | Complications after CA | Symptoms before CA | Symptom Improvement after CA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [11] | 18 | 26 | 1.6–118.3 cm3 (mean, 38.6 cm3) | 31 | 2/26 | 16.2 | MRI, CT | N/A | 0 | 9/26 | 17/26 | 22/23 | 1/23 | 3/31 | 5/18 | 4/5 |
| [12] | 1 | 3 | 0.6–9.8 cm3 (mean, 6.5 cm3) | 3 | 0 | 6 | MRI | 3, 6 | 0 | 3/3 | 0 | 3/3 | 0 | 0 | 1/1 | 1/1 |
| [13] | 13 | 17 | 1.7–14.2 cm (mean, 5.3 cm) | 17 | 1/13 | 11.3 | MRI | 3, 6 | 8/17 | 9/17 | 8/17 | 16/17 | 2/17 | 3/13 | N/A | 14/17 |
| [14] | 5 | 5 | 3–10 cm (mean, 6.6 cm) | 5 | 0 | 6–58 | MRI, CT | N/A | 2/5 | 2/5 | 3/5 | 4/5 | 1/5 | N/A | 5/5 | 3/5 |
| [24] | 50 | N/A | 0.6–1068 cm3 (mean, 111 cm3) | N/A | 0 | 12 | N/A | N/A | N/A | N/A | N/A | N/A | 7/50 | 99.3% | N/A | 83% |
| [25] | 1 | 1 | N/A | 2 | 0 | 9 | N/A | N/A | 0 | 1/1 | 0 | 1/1 | 0 | 0 | 1/1 | 1/1 |
| [26] | 1 | 1 | 416 cm3 | 1 | 0 | 3 | PET/CT | N/A | 0 | 1/1 | 0 | N/A | N/A | N/A | 1/1 | 1/1 |
| [27] | 34 | 41 | 1–593 cm3 (mean, 104.4 cm3) | |||||||||||||
| [28] | 23 | 23 | 0.4–456.5 cm3 (mean, 114.8 cm3) | 30 | 14/23 | 15.4 | MRI, CT | N/A | 11/23 | 6/23 | 11/23 | 81% * | 0/13 + 7/11 | 6/23 | 20/23 | 18/20 |
| Current study | 10 | 18 | 3.4–169 cm3 (mean, 63.6 cm3) | 14 | 4/10 | 53.7 | MRI | 3, 6, 12 | 3/10 | 8/10 | 8/10 | 9/10 | 1/10 | 2/14 | 8/10 | 2/8 |
N/A = not applicable; * = average for 21 EAD tumors.